Sign in
Taking people in United StatesPhase 2

Ruxolitinib skin cream for dermatomyositis rash that has not improved with other treatment

Tests ruxolitinib cream for stubborn skin problems in adults with dermatomyositis.

Key facts

Who runs it
The Cleveland Clinic
Where
Cleveland, United StatesSee the site
Trial code
Registry title
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Status
Recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
1 Jun 2025
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • Ruxolitinib Topical Cream
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dermatomyositis whose skin symptoms continue despite earlier treatment. It tests ruxolitinib 1.5% cream applied to the skin.

Age
18 Years to 89 Years
Sex
All sexes can join.
Disease stage
Classic, juvenile or amyopathic dermatomyositis with active skin disease that has not responded to treatment. A skin biopsy must show dermatomyositis. Affected skin must be BSA>1% to <20%, CDASI activity score > 6, and PGA activity score >2.
Earlier treatment
People must have had systemic corticosteroids and at least one other steroid-sparing systemic treatment, for example methotrexate or mycophenolate mofetil. They must have tried at least one skin medicine that did not work, with the last use more than 2 weeks before joining. Their systemic medicines must have been stable for at least 2 months (60 days) and must stay stable during the trial.

Main reasons for not taking part

  • Little or no active skin disease, or more than 20% of the body skin affected.
  • Used a prescription skin medicine in the previous 2 weeks.
  • Currently taking a Janus kinase inhibitor pill, or poor response to one before, or poor response to a Janus kinase inhibitor cream.
  • Other types of muscle inflammation, such as polymyositis, inclusion body myositis, or overlap myositis.
  • Active cancer other than non-melanoma skin cancer, or dermatomyositis linked to cancer.

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients 18 years and older with refractory cutaneous symptoms related to either classic dermatomyositis (CD), juvenile dermatomyositis (JD), or amyopathic dermatomyositis (AD). Diagnosis will be based on either Bohan and Peter criteria (CD and JD) or Sontheimer's criteria (AD) (19-22)
  • Patients must have had a skin biopsy with histologic features consistent with dermatomyositis and current cutaneous manifestations consistent with dermatomyositis
  • Patients will be considered to have refractory disease if cutaneous manifestations exist despite treatment with systemic corticosteroids and at least one steroid-sparing systemic treatment commonly found to be useful in patients with dermatomyositis. These may include azathioprine, cyclosporine, mycophenolate mofetil, IVIG, methotrexate, hydroxychloroquine, cyclophosphamide, chlorambucil, sirolimus, tacrolimus, and rituximab
  • Patients must have sufficiently active cutaneous involvement of dermatomyositis (BSA>1% to <20%, CDASI activity score > 6, and Physician Global Assessment (PGA) activity score >2)
  • Patients must have tried and failed at least one commonly prescribed topical medication in the past, with the last application of a topical medication to active skin lesions occurring greater than 2 weeks prior to enrollment; o Commonly prescribed topical medications for dermatomyositis include corticosteroids or calcineurin inhibitors (tacrolimus or pimecrolimus)
  • Patients must have been on a stable systemic medication regimen for at least 2 months (60 days) and must agree to keep the regimen stable throughout the study period. As patients with dermatomyositis are commonly treated with combination regimens that include both topical and systemic immunosuppressive medications, any added risk of adverse effects related to ruxolitinib 1.5% cream is considered negligible
  • Patients must be agreeable to use appropriate contraceptive measures while enrolled in the study; Women of childbearing potential must be willing to practice abstinence or use either an oral contraceptive medication or IUD if sexually active; Women of childbearing potential must be willing to have monthly urine pregnancy tests while enrolled in the study; Men of childbearing potential must be willing to practice abstinence or use condoms if sexually active

Who cannot take part

  • Patients who have used a common prescription topical medication within the previous 2 weeks
  • Patients whose cutaneous findings are not consistent with dermatomyositis and/or have previous biopsy results suggestive of an alternative diagnosis
  • Patients not on stable systemic medication regimens for at least 2 months and/or who will not agree to keep the regimen stable throughout the study period
  • Patients who have previously taken a systemic Janus kinase inhibitor but had a poor response, patients who are currently taking systemic Janus kinase inhibitors, or patients who have used a topical Janus kinase inhibitor for their dermatomyositis or any other condition and had poor responses
  • Patients with dermatomyositis who have minimal-to-no active cutaneous disease (mild involvement with < 1% total body surface area involved and/or CDASI activity score of < 6)
  • Patients with clear features of an overlap autoimmune myositis or with an inflammatory myositis not consistent with dermatomyositis, such as polymyositis or inclusion body myositis
  • Patients with an active malignancy other than non-melanoma skin cancer, or with malignancy-associated dermatomyositis
  • Patients younger than 18 years old
  • Patients who have > 20% total BSA involvement of cutaneous dermatomyositis
  • Patients with inflammatory myositis other than dermatomyositis, such as polymyositis or inclusion body myositis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 89 years old?

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Anthony Fernandez, MDTaking people

About the trial

What the trial wants to find out

This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.

The group in the trial

  • TreatmentTreatment being tested

    1.5 % Ruxolitinib cream

    Treatment: Ruxolitinib Topical Cream

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Plain-language title
Ruxolitinib skin cream for dermatomyositis rash that has not improved with other treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06857240, who can take part
Record updated
28 October 2026